CTNM

Contineum TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$19.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$13.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$8.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Evidence quality is good because primary filings and company IR materials are available, but catalyst density is still low and the deterministic prior is neutral-to-slightly negative. Net view is a low-conviction monitoring stance: balance sheet and near-term readout timing are supportive, yet the thesis still hinges on early clinical proof rather than broad operating momentum.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventPIPE-791 chronic pain Phase 1b topline in Q2 2026High impact

Management said topline data from the exploratory PIPE-791 Phase 1b trial in chronic osteoarthritis pain or chronic lower back pain is expected in the second quarter of 2026; the 10-K also frames this study as an efficacy-signal readout for internal development decisions [#PR-2026-03-05][#10-K-2026-03-05].

2026-12-31catalystPROPEL-IPF execution can gradually de-risk the lead programHigh impact

Contineum has initiated patient dosing in PROPEL-IPF, a global Phase 2 study of PIPE-791 in approximately 324 IPF patients, while the 10-K projects trial completion in June 2028; steady enrollment and clean execution are the main medium-term fundamental supports before efficacy data arrive [#PR-2026-03-05][#10-K-2026-03-05].

2026-12-31catalystBalance sheet reduces near-term financing pressureHigh impact

The company reported $262.9 million of cash, cash equivalents and marketable securities at December 31, 2025, and guided runway through mid-2029 after the December 2025 upsized equity raise, which lowers immediate financing risk while PIPE-791 data mature [#PR-2026-03-05][#10-K-2026-03-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology